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Staphylococcus aureus – це універсальний бактеріальний патоген, який здатний швидко розвивати резистентність 
до нових антибіотиків, перш за все за рахунок великого арсеналу факторів вірулентності, основна роль яких зво-
диться до поширення захворювання шляхом подолання імунних факторів захисту господаря. Широке поширення 
в стаціонарах, а також поява клінічних ізолятів Staphylococcus aureus, стійких до метициліну у позалікарняному 
середовищі, залишає лікарів без ефективних засобів контролю над цією інфекцією. Метою нашої роботи став ана-
ліз основних факторів вірулентності S.аureus і шляхів впливу на них з позиції етіопатогенетичної терапії. Склад-
ність лікування бактеріальних інфекцій визначає актуальність впровадження в медичну практику альтернативних, 
більш ефективних засобів профілактики і лікування захворювань, до яких бактерії не здатні так легко і швидко 
розвивати резистентність. Поряд із загальними механізмами, які формують стійкість до антибіотиків, S.aureus 
продукує безліч індивідуальних факторів вірулентності, які моделюють імунну відповідь, впливаючи на виживання 
макроорганізму. Фактори вірулентності, що виробляються S. aureus різноманітні і мають здатність не тільки ви-
кликати лізис клітин, але і стимулювати відторгнення і руйнування тканин. Важливо відзначити, що більшість з 
них здатність специфічно видозмінювати як вроджені, так і адаптивні імунні реакції, включаючи пригнічення ак-
тивації комплементу, нейтралізацію нейтрофілів і порушення функції фагоцитів. Стратегії пригнічення факторів 
вірулентності можуть варіювати від використання невеликих молекул-інгібіторів або повноцінних антитіл, до ство-
рення анатоксинів та білків вірулентності. Особливий інтерес представляють ті інгібітори, які, володіють перехре-
сною реактивністю по відношенню до множинних факторів вірулентності, а також інгібітори, головна мета яких 
представляє собою глобальний регулятор з багатоцільовою активністю, наприклад agr оперон. Активні дослі-
дження з вивчення конкретних альтернативних антивірулентних методів лікування тяжких форм захворювань, 
викликаних S.aureus потенційно можуть зупинити величезний потік проблем і труднощів, з якими ми стикаємося в 
постантибіотичну еру. 
Ключові слова: Staphylococcus aureus, фактори вірулентності, бактеріальні інфекції 
Staphylococcus aureus is a universal bacterial pathogen, which is able to develop the resistance to new antibiotics, by 
means of virulence factors, whose main function is the spread of diseases by inhibiting the immune factors of host de-
fense. Its wide spread at in-patient departments and also the presence of clinical probationary wards Staphylococcus 
aureus, resistant to methicillin at out-patient departments, deprive the doctors of effective means for control of the in-
fection. Complications caused by MRSA lead to hospitalization and indices of lethality. The aim of the paper is to analyze 
the main factors of S. аureus virulence and ways the of its interaction as a result of etiological and pathogenetic treat-
ment. Complexity of treatment of bacterial infections is determined by alternative ways of prevention and treatment of 
diseases to which bacteria are not able to develop resistance. Along with general mechanisms that form antibiotic resis-
tance, S. aureus produces many individual virulence factors that model the immune response, affecting the survival of 
the microorganism. The virulence factors produced by S. aureus are diverse and have the ability not only to cause cell 
lysis, but also to stimulate tissue rejection and destruction. It is important to determine that many specific factors of 
virulence caused by S. aureus, have ability to change both congenital and adaptive immune reactions including inhibition 
of complement activation, neutrophils neutralization, phagocytes inhibition. Strategies for inhibiting virulence factors can 
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range from using small inhibitor molecules or full-fledged antibodies to creating toxoids and virulence proteins. Great in-
terest is focused upon those inhibitors that have cross-reactivity with respect to multiple virulence factors, as well as in-
hibitors, the main target of which is a global regulator with multi-purpose activity, for example, agr operon.  Active re-
search into the specific alternative antivirulent treatments for severe diseases caused by S. aureus can potentially settle 
a number of problems and difficulties of post-antibiotic era. 
Key words: Staphylococcus aureus, virulence factors, bacterial infections 
Staphylococcus aureus is a universal bacterial patho-
gen, which is able to develop the resistance to new antibi-
otics, by means of virulence factors, whose main function 
is the spread of diseases by inhibiting the immune factors 
of host defense. Its wide spread at in–patient departments 
and also the presence of clinical probationary wards 
Staphylococcus aureus, resistant to methicillin (methicillin-
resistant Staphylococcus aureus, MRSA) at out-patient 
department deprive the doctors of effective means for con-
trol of the infection. Complications caused by MRSA lead 
to hospitalization and indices of lethality. Complexity of 
treatment of bacterial infections is determined by alterna-
tive ways of prevention and treatment of diseases to which 
bacteria are not able to develop resistance. 
Along with general mechanisms that form antibiotic 
resistance, S. aureus produces many individual virulence 
factors that model the immune response, affecting the 
survival of the microorganism [1]. The virulence factors 
produced by S. aureus are diverse and have the ability 
not only to cause cell lysis, but also to stimulate tissue 
rejection and destruction. It is important to take into ac-
count that many specific factors of virulence caused by S. 
aureus have the ability to change both congenital and 
adaptive immune reactions including inhibition of com-
plement activation, neutrophils neutralization, phagocytes 
inhibition [2].  
The aim of the paper is to analyze the main factors of 
S. аureus virulence and the ways of its interaction as a 
result of etiological and pathogenetic treatment.  
Nowadays, alternative ways of staphylococci resis-
tance were studied and the obtained results were ana-
lyzed [3] (Figure 1). 
 
 
Figure 1. Factors of virulence, their functions and ways of inhibition [3]. 
One of the most significant pathogenesis of staphylo-
coccal infections is the additional gene regulator (acces-
sory gene regulator (agr)) of the operon system (a struc-
tural unit consisting of related genes that regulates other 
genes responsible for protein synthesis) was first discov-
ered in the late 80s years of the last century. A therapeu-
tic strategy focused on the agr system can be very effec-
tive, since by acting on it, it is possible to destroy many of 
the virulence factors associated with it, rather than op-
pressing each separately [4]. Determining the specific 
role of agr in the course of infection is complicated by dif-
ferent models of the course of diseases, the existence of 
different patient populations. When modeling acute infec-
tions in mice, there is clear evidence that agr is an impor-
tant virulence factor [5]. In humans, a strong association 
has been found between the colonization of S. aureus in 
nosocomial infections with agr dysfunction [6]. In other 
studies, association was not found between agr defi-
ciency and negative clinical outcomes. To establish a 
clear link between the agr operon and specific pathoge-
netic processes, further studies are needed because cur-
rent research has led to various conclusions that may be 
associated with strain-specific differences. Considering 
well known factors of virulence, which regulate agr, strat-
egy of interaction can be a target of antivirulent ap-
proaches to the treatment. During experiment on mice it 
has been established the influence of agr demonstrates 
the decrease of virulence of S. аureus associated pneu-
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monia and dermonecrosis. Recently researches Sully et 
al., were published where authors can define the small 
molecule of inhibitor AgrA affecting agr operon and it is 
called savirin (S. aureus virulence inhibitor). Using a 
model of infection of the skin and soft tissues in mice, the 
authors were able to define a reduction in tissue damage 
and a reduction in the bacterial load in the treatment of 
infections with savirin. Savirin blocks the binding of AgrA 
to its promoter sites, which further contributes to a 
change in the expression of most secreted virulence fac-
tors. Treatment by savirin does not inhibit “quorum 
sensing” with Staphylococcus epidermidis, and it indi-
cates the specificity of the given inhibitor to S. aureus [7]. 
Inhibiting action on agr also has natural received from 
Photobacterium halotolerans cyclodepsipeptides called 
Solonamide В (Solonamide B) [8]. Additional inhibitor 
cluster of agr-genes was described by foreign scientists 
in 2015 [9]. They defined that ω-hydroxyemodin (ОНМ), 
small connection selected from Penicillium restrictum in-
hibits the function of quorum sensing agr operon by bind-
ing with promoter protein and by preventing the interac-
tion of DNA. In the course of the experiment, the treat-
ment of S. aureus infections in mice with OHM helped to 
reduce the size of the lesion, as well as the reduction of 
colony forming units (CFU colony forming unit) of bacte-
ria.  
The virulence factors also include α-toxin, which is a 
secreted protein capable of lysing cells, forming pores on 
their membrane [10]. In a study using the α-toxin anti-
body LC10 on a pneumonia model in mice, it was shown 
that LC10 in combination with vancomycin or linezolid 
improves the survival of mice compared to monotherapy. 
Kennedy et al. demonstrated that immunization to α-toxin 
using antiserum or a non-toxic form of α-toxin (HlaH35L ) 
results in a reduction of skin lesions and dermonocrosis 
in mice with S. aureus infection by reducing α-toxin oli-
gomerization [11]. Nagy developed cross-reactive anti-
body which is able to bind conformative epitopes of α-
toxin, γ-hemolysine and Panton-Valentine leukocidin. Us-
ing the strain MRSA USA300, they were able to increase 
the survival rate of mice by injecting this antibody both 
intranasally and intravenously [12]. α-toxin is an ex-
tremely important virulence factor for S. aureus, and re-
cent studies have shown that inhibition of this toxin may 
lead to improved results in the treatment of bacterial in-
fections. It has been proved that over-expression of α-
toxin correlates with increased virulence of the strain CA-
MRSA ST93 [13]. Treatment using a single antibody 
aimed simultaneously on most virulence factors may be 
quite effective and promising in the future. Currently, in a 
second phase of clinical trials, Astra Zeneca is testing a 
compound that acts on α-toxin called MEDI4893.  
Phenol-soluble modulins (phenol-soluble modulin 
(PSMs)) include a family of amphipathic alpha-helical 
peptides (PSMα, PSMβ and S. aureus δ-toxin associated 
with PSMα) that perform various functions in the patho-
genesis of staphylococcal diseases [14]. Unlike many 
virulence factors produced by S. aureus, which are en-
coded by mobile genetic elements, PSM are encoded in 
the main genome and therefore are present in almost all 
strains of S. aureus [13]. The presence of PSMα and 
PSMβ in strains of S. aureus is clinically important, which 
makes them potential targets for antivirulent therapy. It 
should also be emphasized that phenol-soluble modulins 
play different roles both in the pathogenesis of S. aureus-
associated diseases and in the initial colonization of hu-
man epithelial tissues. PSMα peptides are cytolytic, with 
the ability to lyse various human cells, including white 
blood cells and red blood cells. PSMβ peptides are in-
volved in the distribution of biofilms, but have less cyto-
lytic activity [15]. In a model of cutaneous S. aureus in-
fection, researchers and Kahlenberg determined that a 
strain with impaired synthesis of PSMα and PSMβ did not 
lead to any significant damage [16]. In animals treated 
with anti-PSMβ, researchers found a decrease in the 
spread of infection to organs, including the liver, spleen 
and lymph nodes associated with a biofilm on a catheter 
[17]. However, immunization against the PSMα-type, 
which has more aggressive cytolytic properties, requires 
further study. The second treatment strategy involves 
blocking the export of PSM through a phenol-soluble 
modulin transporter (phenol-soluble modulin transporter, 
or Pmt, ABC transporter). This approach is justified for 
the purpose of broad inhibition of PSM, since Pmt is a 
specialized transporter for all types of PSM and is en-
coded in the main genome [18]. In conclusion, the phe-
nol-soluble modulins encoded by the genome play an 
important role in the pathogenesis of S. aureus-
associated infections, including lysis of host cells, the 
formation of biofilms, the initiation of inflammatory reac-
tions. Inhibition of these proteins can help increase the 
survival rate of MRSA infections. There are several prom-
ising ways to influence PSM: directly through the use of 
antibodies and indirectly by targeting export and regula-
tory pathways, and given their complex and diverse 
structure, successful inhibition of PSM virulence is likely 
to occur through a multifaceted approach.  
Protein A (SpA) presents a protein, which is released 
during bacteria growth and is coded as spa-gene. Many 
factors of virulence S. aureus, protein A is regulated by 
system agr, and expression of protein A specifically is 
inhibited by RNAIII [19]. Protein A contains two areas 
with clear structural and functional differences: area X 
and binding immunoglobulin’s domain. X area is respon-
sible for joining to cellular wall of protein А; N-terminal 
protein area A contains 5 immunoglobulin-binding do-
mains (E, D, A, B, C). That’s why, protein A presents pro-
tein, which is fixed by cellular wall using antibodies aimed 
at protein A and contains gold nanoparticles, scientists 
(Zanjani) could affect S. aureus by photothermal therapy 
[20].  
An antibody aimed at a bacterial cell, followed by irra-
diation with a gold nanoparticle, induces heating, trans-
fers energy and causes physical damage to the bacterial 
cell. This approach to exposure to bacteria using conju-
gated antibodies to specific factors is very specific, since 
protein A and gold nanoparticles in mammalian systems 
have a low level of toxicity [21]. The proposed method 
can be used in combination or completely replace antibi-
otic therapy of bacterial infections. Over time, resistance 
of various mutations to the antibody’s binding site is likely 
to form, and the combination of photothermal therapy and 
standard antibiotic treatment can be an innovative and 
new approach to the treatment of bacterial infections. 
Synthesis of antibodies to α-toxin, as one of the methods 
for neutralizing the S. aureus virulence factors, has 
reached the second phase of clinical trials, so we hope to 
succeed in studying SpA antibodies in the future.  
The virulence factor leukocidin Panton-Valentine 
(PVL), produced by S. aureus, is a toxin that destroys 
leukocytes and is associated with severe skin infections, 
necrotic pneumonia. Most of the diseases caused by 
PVL-positive strains are sporadic, in particular, small out-
breaks of necrotizing staphylococcal infections of the skin 
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and soft tissues are recorded, but more and more severe 
pneumonia with high mortality occurs, which mainly affect 
healthy young people. Clinical studies have determined 
that only PVL-positive strains of S. aureus can compli-
cate the course of influenza in healthy young patients 
with rapid progression up to severe necrotizing pneumo-
nia. In contrast, PVL-negative strains usually cause non-
specific S. aureus pneumonia in the elderly, where the 
risk of fulminant outcome is much lower (aged ≥60 
years). Despite the close correlation between the severity 
of the disease and the presence of PVL genes, the defini-
tion of the role that PVL plays during infection remains 
controversial. Some studies have emphasized the impor-
tance of PVL in the pathogenesis of the disease, while 
others refute this hypothesis [22]. Interesting results pre-
sented by Otto and others determined that expression of 
PVL and other virulence factors such as SpA can be in-
hibited using sublethal concentrations of antibiotics [23]. 
Assuming that PVL does play a significant role in human 
infection, blocking its activity with a receptor inhibitor can 
provide important protection during infection [24]. The 
disadvantage of using PVL inhibitors is that most strains 
of HA-MRSA do not have this gene, and they will simply 
be ineffective against many strains of HA-MRSA. In addi-
tion, there are also virulent strains of CA-MRSA, which 
lack PVL genes [25]. Therefore, strain-typing before 
treatment can be one of the approaches of selective anti-
virulent therapy.  
A unique group of virulence factors are staphylococ-
cal enterotoxins (SE), which, due to their ability to bind to 
human T-cells and induce hyperstimulation, are called 
“superantigens” [26]. Staphylococcal enterotoxins (SE) 
are very resistant to heat and proteolysis and are the 
main cause of food poisoning [27]. It has been identified 
twenty-one staphylococcal enterotoxin (SE-A - SE-U) 
[28]. They belong to category B substances according to 
the CDC classification, since a small amount of protein it 
is necessary for the onset of symptoms and their rapid 
spread [28]. Different strains of S. aureus produce differ-
ent amounts of SE-toxin ranging from 1 μg / ml to 10 ng / 
ml.  
The work of Bavari et al. demonstrates that immuni-
zation of mice with antibodies to one SE causes cross-
resistance to other SE-toxins [29]. Mice were injected 
with recombinant antibodies against one specific SE and, 
further, they formed partial immunity to other SE iso-
forms. The use of the SE-B mutated subunit as a vaccine 
approach also leads to increased immunity against the 
toxicity of SE-B. In piglets vaccinated with the non-toxic 
form of SE-B, IgG and IgA production increased, which 
cross-reacted with wild-type SE-B, which indicates the 
possibility of using this method as an immunization strat-
egy [30]. Recently Reddy et al. able to create a recombi-
nant peptide consisting of parts of SE-A and toxic shock 
toxin 1, which is able to generate an immune response 
against these toxins [31]. Preventive immunization of 
mice led to an increase in their survival by 50-80% with 
the introduction of a lethal dose of SE-A.  
Considering promising results regarding the formation 
of immunity against staphylococcal enterotoxins using 
antibodies, aptamers or mutated forms of the SE protein 
itself as vaccines, they can provide significant potential in 
the treatment of severe forms of diseases associated 
with S. aureus.  
Bacterial two-component systems (Bacterial two-
component systems - TCS) are among the basic means 
of vital activity of bacteria that are able to interact with the 
environment [26, 31]. As the name suggests, TCS con-
sists of two proteins: sensory kinase, which responds to a 
signal and a response regulator that binds to DNA. In S. 
aureus, two-component systems may affect the virulence 
of the bacteria. The agr system is one of the important 
regulators of virulence and its structure is also repre-
sented by a two-component protein, i.e. TCS consisting 
of an AgrA reaction regulator and AgrC kinase. TCS 
saeR / S by reducing reactive oxygen species protects 
the bacterium from host proteins, thereby masking it from 
the innate immune response, reducing the expression of 
IL-8 and increasing the expression of leukocidins [32].  
Using a natural substance isolated from Glycyrrhiza, 
called 18β-glycyrrhetinic acid (GRA), researchers were 
able to determine that at high concentrations the com-
pound is able to destroy S. aureus, and in sublethal con-
centrations to inhibit virulence genes, including saeR 
[33]. The authors determined that during the treatment of 
the infection with the GRA, the number of CFUs did not 
change significantly, while the size of the damage in the 
mice was significantly reduced, which indicates not only 
the antibiotic effect, but also the suppression of virulence.  
Using a small molecular inhibitor of the synthesis of 
fatty acids of staphylococcus of the second type called 
AFN-1252, Parsons et al. could show that it significantly 
reduces the expression of sae genes [34]. With the intro-
duction of repeated doses of AFN-1252, the concentra-
tion of microorganisms decreased by almost five orders 
of magnitude. The authors noted that the treatment also 
had a significant effect on the level of transcription of the 
sae gene, since the cells that were actively growing had 
a much more stable decrease in sae compared to when 
bacteria were processed in the stationary phase [34]. 
This work once again confirmed the possibility of influ-
encing component systems, thereby exerting a positive 
influence on the course of infection, however, and the 
dynamics of bacterial growth can significantly affect the 
effectiveness of treatment.  
It has been determined that inhibitor TCS causes bac-
tericidal effects [35, 36]. In particular, such influence on 
two-component system WalK/WalR (YycG/YycF), which 
is necessary for cells in S. aureus, leads to bacteria 
death. Okada et al. determined natural component in 
Streptomyces sp. MK632-100F11 and called it Walkmy-
cin B, which caused antibacterial activity against B. Sub-
tilis [35]. Connection also demonstrates antibacterial pe-
culiarities to both strains MRSA and MSSA. It has been 
indicated that in result of medicinal drug action by de-
crease of auto-phosphorylation vancomycin inhibits com-
ponents of the protein WalK TCS. This interaction be-
tween vancomycin B and protein TCS was approved by 
superficial plasmonic resonance with using B. Subtilis 
[35]. Analogue research was also done by Igarashi et al. 
authors could determine new type of Streptomyces, so 
called MK844-mF10, which is able to produce active 
substance to correlation to WalK B. Subtilis and called it 
waldiomycin [36]. Waldiomycin, has structural similarity 
with diozamycin an also inhibits the activity of some 
strains of S. aureus, including two different strains of 
MRSA with minimal inhibition concentration (MIC) 16 
mkg/ml. It has been indicated that waldiomycin prevents 
auto-phosphorylation WalK both for released protein B. 
subtilis and for S. aureus. Two-component systems re-
main relevant and encouraging field of research in the 
area of S. aureus virulence both in terms of studying the 
degree of inhibition of SaeR and SaeS and as a target of 
antibiotic therapy.  
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S. aureus has a golden or yellow color due to pig-
ments from the group of carotinoids, the main of which is 
Staphyloxanthin - β-D-glucopyranosyl-1-O- (4,4'-
diaponeurosporen-4-octa) -6-O- (12 –methyltetradeca-
noate) [37]. Staphyloxanthin can be a critical factor in the 
virulence of infections caused by S. aureus because of its 
ability to neutralize antiseptic substrates of various 
chemical groups, such as superoxide, hydrogen perox-
ide, hypochlorous acid, aldehyde-containing drugs.  
Staphyloxanthin can be critical factor of virulence caused 
by S. aureus to neutralize antiseptic substrates of chemi-
cal groups such as superoxide, hydrogen peroxide, hy-
pochlorus acid, aldehyde containing drugs. Staphyloxan-
thin allows bacteria to detoxify reactive forms of oxygen, 
generated mainly by neutrophils. Mutant colonies of the 
strain S. aureus in the absence of staphyloxanthin quickly 
die under the influence of neutrophils. Synthesis of this 
pigment is regulated by the rsbUVWsigB system. When a 
mutation occurs in one of the genes of the system, the 
synthesis of staphyloxanthin is reduced or completely in-
hibited. Therefore, the study of factors affecting the syn-
thesis of carotinoids in S. aureus is very important for un-
derstanding the conditions of variability of microorgan-
isms of this species. 
The search for staphyloxanthin inhibitors can be car-
ried out by treating S. aureus with a compound that re-
duces its golden color. Recently, Chen and his col-
leagues used this approach to screen 412 drugs in order 
to find substances that inhibit staphyloxanthin biosynthe-
sis [17]. They were able to select only three compounds 
that led to the loss of pigment in S. aureus: ibandronate, 
terbinafine and naftifine, the last of which inhibited the 
production of staphyloxanthin most clearly. Bacteria 
processed by naftifine determined increased sensitivity to 
hydrogen peroxide and possibility of survival in blood of 
person decreased in 20 times. 70 % of mice received 
treatment by naftifine survived during 12 days, as against 
control group where all mice died in 24 hours. Using 
methods of expression E.coli, authors could determine 
that naftifine also was able to inhibit activity of enzyme 
CrtN. Despite promising results, the authors note that not 
all strains of S. aureus produce staphyloxanthin, and, 
therefore, treatment is limited to individual strains [17]. 
Yet in cases where it is present in bacteria, the use of 
inhibitory molecules may be a very promising direction in 
the future. Taken together, these data show that inhibi-
tion of the synthesis of staphyloxanthin can be a vital 
strategy, because the effect on virulence, especially with 
the selection of different models of computer inhibition, 
will help identify various modifications in the synthesis of 
already existing compounds.  
Conclusions 
Given the prevalence of MRSA and, accordingly, cer-
tain limitations in the creation of new antibiotics, the 
strategy of creating drugs as an alternative treatment for 
diseases aimed at specific inhibition of the activity of S. 
aureus virulence factors remains an active and promising 
direction. Mechanistic studies explaining the structural 
and functional properties of these factors open up new 
possibilities for studying ways to inhibit or inactivate them 
and, ultimately, improve pathogenetic treatment. Strate-
gies for inhibiting virulence factors can range from using 
small inhibitor molecules or full-fledged antibodies to cre-
ating toxoids and virulence proteins. Great interest is 
considered to those inhibitors that have cross-reactivity 
with respect to multiple virulence factors, as well as in-
hibitors, the main target of which is a global regulator with 
multi-purpose activity, for example, agr operon. Active 
research into the study of specific alternative antivirulent 
treatments for severe diseases caused by S. aureus can 
potentially stop huge stream of problems and difficulties 
of post-antibiotic era.  
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